

Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date:	October 21, 2015
Revision date:	January 21, 2020, May 19, 2020

**OFEV® (nintedanib)**

**LENGTH OF AUTHORIZATION:** Up to 6 months

**REVIEW CRITERIA:**

**Idiopathic Pulmonary Fibrosis**

- Patient must be  $\geq 18$  years old.
- Must be prescribed or in consultation with a pulmonologist.
- Confirmation of idiopathic pulmonary fibrosis through exclusions of other known causes of interstitial lung disease: Domestic and occupational environmental exposures, drug toxicity or connective tissue disease.
- Confirmation of diagnosis via lung biopsy for idiopathic pulmonary fibrosis diagnosis **OR** high resolution computed tomography.
- Documented pulmonary function tests within the past 60 days reflecting Forced Vital Capacity (FVC)  $\geq 50\%$ .
- Baseline percent predicted diffusing capacity of the lung for carbon monoxide is  $\geq 30\%$  for idiopathic pulmonary fibrosis.
- Documentation submitted that the patient is a nonsmoker or has been abstinent for at least six weeks.
- Patient must obtain a liver function test prior to starting treatment.

**Systemic Sclerosis-Associated Interstitial Lung Disease**

- Confirmation of systemic sclerosis-associated interstitial lung disease.
- Documentation submitted that the patient is a nonsmoker or has been abstinent for at least six weeks.
- Confirmation of diagnosis via high resolution computed tomography.
- Documented pulmonary function tests within the past 60 days reflecting Forced Vital Capacity (FVC)  $\geq 40\%$ .
- Patient must obtain a liver function test prior to starting treatment.

**Chronic Fibrosing Interstitial Lung Diseases**

- Confirmation of chronic fibrosing interstitial lung diseases with a progressive phenotype;
- Documentation submitted that the patient is a nonsmoker or has been abstinent for at least six weeks.
- Documented pulmonary function test within the past 60 days reflecting Forced Vital Capacity (FVC)  $\geq 45\%$  of predicted
- Baseline percent predicted diffusing capacity of the lung for carbon monoxide (DLCO) between 30-79%
- Patient must obtain a liver function test prior to starting treatment.



Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date:	October 21, 2015
Revision date:	January 21, 2020, May 19, 2020

CONTINUATION OF THERAPY:

- Documentation of improvement or effectiveness of therapy (< 200ml decrease in FVC or <10% decline in percent predicted FVC) for idiopathic pulmonary fibrosis.
- Documentation of improvement or effectiveness of therapy for systemic sclerosis-associated interstitial lung disease.
- Documentation that the rate of decline of lung function has slowed for chronic fibrosing interstitial lung diseases.
- Clinical documentation that the recipient is tobacco free.

DOSING & ADMINISTRATION:

150mg by mouth twice daily 12 hours apart with food. Swallow whole with liquid.